Preliminary results from the COSMIC-313 clinical trial have ben released. The results showed that adding cabozantinib to nivolumab plus ipilimumab increased the time to when the treatment stopped working and the cancer started growing again in patients who had not previously been treated and who had advanced intermediate- or poor-risk kidney cancer.
There were 855 patients in the phase 3 COSMIC-313 trial from 177 international hospitals. Patients were randomly allocated to receive either nivolumab and ipilimumab plus cabozantinib or nivolumab and ipilimumab plus placebo.
The study showed that compared with nivolumab plus ipilimumab alone, the triplet of cabozantinib plus the immunotherapies resulted in a 27% reduction in the risk of disease progression or death. It is too early in the trial to determine overall survival times for the triplet compared to nivolumab plus ipilimumab, and the trial is ongoing to collect this information.
There were no new side effect reported compared to previous trials using the medicines alone or in combination.